Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2010 - 02 - 27

LUSOFARMACO: substantial support in rare diseases

"Rare Diseases in Young Adults" is the title of the latest publication sponsored by Lusofarmaco, member company of the Menarini Group, recently distributed to Italian physicians.

The Menarini Group has always given particular attention to rare diseases, dedicating research projects to ‘orphan’ diseases such as: the study for a vaccine against cancer of the ovaries, a project on a third generation anti-cancer drug against microcitoma of the lung, and the development of a new biotechnological drug for the treatment of a rare and serious disease afflicting children in paediatric age.

" We will continue to focus on rare diseases by providing updated scientific texts, and this is a concrete and substantial commitment undertaken by the company in order to support both the GP and his patients. Indeed this latest publication includes, for each pathology cited, the information necessary to support the physician, ranging from photographic material to patient associations and exemption codes …" commented Dr. Giulio Vignaroli, General Manager of Lusofarmaco.